Effects of Sublingual and Transdermal Administration of Nitroglycerin for Coronary CT Angiography on Image Quality

• Status: Completed
• Trial end date: 2018-08-02
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate image quality of coronary CT angiography (cCTA) after sublingual and transdermal administration of Nitroglycerin. Aim of this prospective research study is to investigate equivalence on image quality after sublingual or transdermal Nitroglycerin administration (H0).

Furthermore, the feasibility of transdermal Nitroglycerin administration will be evaluated.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Massachusetts General Hospital
• Treatments: Nitroglycerin

Criteria

Inclusion Criteria:

1. Scheduled cCTA with contrast.

2. Able to comprehend and sign the consent form.

Exclusion Criteria:

1. Known hypersensitivity to glyceryl trinitrate, and related organic nitrates.

2. Acute circulatory failure associated with marked hypotension (shock).

3. Conditions associated with elevated intracranial pressure, cerebral haemorrhage and head trauma.

4. Closed-angle glaucoma.

5. Phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil (Viagra®), tadalafil (Cialis), or vardenafil (Levitra) within the last 24 hours

6. Unstable clinical conditions (i.e. hemodynamic instability, arrhythmias)

7. Critical aortic stenosis

8. Systolic blood pressure < 90 mmHg

9. Pregnant or lactating female; premenopausal women with a positive urine pregnancy test.

10. Age under 18

11. Unwilling or unable to inform consent.